J Li1, M Yu2, Z Liu3, B Liu4. 1. a Department of Oncology , The Central Hospital of Linyi , Yishui , Shangdong , China. 2. b Department of Operating Room , The Affiliated Hospital of Qingdao University , Qingdao , Shangdong , China. 3. c Department of Oncology , The Affiliated Hospital of Qingdao University , Qingdao , Shangdong , China. 4. d Department of Thoracic Surgery , The Central Hospital of Linyi , Yishui , Shangdong , China.
Abstract
Background: MicroRNAs (miRNAs) are becoming recognized as novel diagnostic and prognostic biomarkers in several malignancies, including non-small-cell lung cancer (NSCLC). miR-25 is overexpressed in small cell lung cancer (SCLC) and NSCLC tissues, and high miR-25 expression is associated with poorer overall survival of women with lung ADC. We hypothesised links between serum miR-25 levels and clinicopathological characteristics, diagnosis and prognosis of NSCLC patients. Methods: Serum miR-25 was determined by real-time quantitative polymerase chain reaction in 128 NSCLC patients and 128 healthy controls, and links between miR-25 level and cliniopathological characteristics including diagnosis and prognosis were explored. Results: Median (IQR) serum miR-25 levels were significantly increased in NSCLC compared to healthy controls at 0.86 relative units (0.14-1.78) versus 0.23 (0.08-0.96) (P < 0.001). Using a cut-off of 0.67 units, miR-25 had a sensitivity of 76.4%, specificity of 84.6%, accuracy of 72.6%, positive predictive value of 92.8% and negative predictive value of 68.5% for the diagnosis of NSCLC. High serum miR-25 level was significantly associated with gender (P = 0.042), tumour stage (P = 0.014) and lymph node metastasis (P < 0.001). In multivariate analyses, miR-25 was an independent prognostic factor for overall survival and relapse-free survival. Conclusions: Serum levels of miR-25 could improve NSCLC screening, and be a useful diagnostic and prognostic marker of NSCLC.
Background: MicroRNAs (miRNAs) are becoming recognized as novel diagnostic and prognostic biomarkers in several malignancies, including non-small-cell lung cancer (NSCLC). miR-25 is overexpressed in small cell lung cancer (SCLC) and NSCLC tissues, and high miR-25 expression is associated with poorer overall survival of women with lung ADC. We hypothesised links between serum miR-25 levels and clinicopathological characteristics, diagnosis and prognosis of NSCLCpatients. Methods: Serum miR-25 was determined by real-time quantitative polymerase chain reaction in 128 NSCLCpatients and 128 healthy controls, and links between miR-25 level and cliniopathological characteristics including diagnosis and prognosis were explored. Results: Median (IQR) serum miR-25 levels were significantly increased in NSCLC compared to healthy controls at 0.86 relative units (0.14-1.78) versus 0.23 (0.08-0.96) (P < 0.001). Using a cut-off of 0.67 units, miR-25 had a sensitivity of 76.4%, specificity of 84.6%, accuracy of 72.6%, positive predictive value of 92.8% and negative predictive value of 68.5% for the diagnosis of NSCLC. High serum miR-25 level was significantly associated with gender (P = 0.042), tumour stage (P = 0.014) and lymph node metastasis (P < 0.001). In multivariate analyses, miR-25 was an independent prognostic factor for overall survival and relapse-free survival. Conclusions: Serum levels of miR-25 could improve NSCLC screening, and be a useful diagnostic and prognostic marker of NSCLC.
Authors: Chang Liu; Eric Kannisto; Guan Yu; Yunchen Yang; Mary E Reid; Santosh K Patnaik; Yun Wu Journal: Front Genet Date: 2020-03-20 Impact factor: 4.599